Business Context and Reporting Period
This Form 8-K was filed by ChromaDex Corporation on November 5, 2015, reporting events occurring on October 30, 2015. The filing discloses the entry into a material definitive agreement with The Procter & Gamble Company (P&G).
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. It notes that P&G has paid an upfront payment to ChromaDex and will make additional milestone-based payments, but the specific amounts are not disclosed in this text.
Material Changes and Agreement Terms
- Agreement Type: Joint Development Agreement (JDA) entered on October 30, 2015.
- Subject Matter: Development of stable forms of ChromaDex's NIAGEN® nicotinamide riboside ("Stable NR").
- Cost Allocation: P&G will bear the costs of development, including human clinical studies and consumer research.
- Exclusivity: P&G receives exclusive rights to Stable NR for specific consumer product fields for both existing and new P&G branded products.
- Future Supply: Parties must commence good faith negotiations for an exclusive supply agreement by the later of October 30, 2016, or six months after Stable NR development.
- Term: Two years, terminable by either party with 90 days' written notice.
Outlook, Risks, and Management Commentary
Management highlights the strategic partnership with a major consumer goods company to advance the commercialization of Stable NR. The filing does not explicitly list risks or contingencies beyond the standard termination clause and the requirement for future negotiations regarding supply agreements. The full agreement is attached as an exhibit to the upcoming Form 10-K.
Investor Verification Checklist
- Verify the specific dollar amount of the upfront payment and the criteria for milestone payments in the full agreement.
- Review the definition of "specific consumer product fields" to understand the scope of P&G's exclusivity.
- Monitor the timeline for the commencement of supply negotiations (October 30, 2016, or six months post-development).
- Confirm the status of Stable NR development and any associated clinical study results in future filings.